GlassScriptPhysician profile
Raymond Rs Heyde
NPI 1861484263
$3,216.38
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $969 · 2020: $534 · 2021: $1,085 · 2022: $629.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $736.11 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $562.19 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $370.93 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $356.82 | 2019-2022 | |
| Alcon Vision LLC | $277.42 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $209.40 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $134.99 | 2019-2021 | |
| Abbvie INC. | $123.92 | 2022 | |
| Genentech USA, INC. | $122.03 | 2022 | |
| Sun Pharmaceutical Industries INC. | $100.87 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $92.61 | 2019-2021 | |
| Abb Con-Cise Optical Group LLC | $33.30 | 2022 | |
| Ivantis, INC | $27.42 | 2021 | |
| Rxsight INC | $23.71 | 2021 | |
| Bausch & Lomb Americas INC. | $23.54 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $21.12 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Heyde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.